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Bypassing the proline/thiazoline requirement of
the macrocyclase PatG†
E. Oueis, a H. Stevenson,a M. Jaspars,b N. J. Westwood a and
J. H. Naismith *acde
Biocatalysis is a fast developing field in which an enzyme’s natural
capabilities are harnessed or engineered for synthetic chemistry.
The enzyme PatG is an extremely promiscuous macrocyclase
enzyme tolerating both non-natural amino acids and non-amino
acids within the substrate. It does, however, require a proline or
thiazoline at the C-terminal position of the core peptide which
means the final product must contain this group. Here, we show
guided by structural insight we have identified two synthetic routes,
triazole and a double cysteine, that circumvent this requirement.
With the triazole, we show PatGmac can macrocyclise substrates
that do not contain any amino acids in the final product.
Enzymes provide useful tools as catalysts to achieve complex
transformations in organic synthesis that either because of
stereochemical variability or high activation energy are diﬃcult
to accomplish chemically. Concerns about environmental costs
of organic solvents and waste streams have further driven the
use of enzymes. Advances in recombinant DNA technology and
directed evolution strategies have improved the availability,
stability, and reactivity of enzymes.1 Innovations in protein
immobilisation,2 microfluidic reactors,3 and protein design4
have further extended their utility. A wide range of transforma-
tions including hydrolytic reactions, reductive and oxidative
reactions, transfer reactions, and carbon–carbon bond for-
mation are catalysed by enzymes.5
Macrocyclisation is an important modification in the synthesis
of many biologically active compounds, including not only natural
products but also drug leads.6 It is argued that macrocyclic
compounds (whether peptidic or not) are better drug leads
for challenging molecular targets such as protein–protein
interactions.7 Hence, the strong interest in these molecules as
therapeutics.8 This has driven the development of a number of
new technologies for the generation of diverse libraries of cyclic
peptides in vivo (SICLOPPS: split-intein circular ligation of pep-
tides and proteins)9 or the construction of non-standard peptide
libraries in vitro (RaPID: random non-standard peptide integrated
discovery)10 for example. Macrocyclic peptides are generally
acknowledged as structurally diverse, rigid and stable (chemically
and enzymatically), highly desirable properties for therapeutic
applications, despite their size.11 Significant progress has been
reported on predicting membrane permeability of large cyclic
compounds that lie outside Lipinski’s rule of 5, allowing for a
more rational approach to macrocycle drug design.12 Several
enzyme macrocyclases are known, and some have already been
exploited for biocatalysis. Butelase 1 macrocyclises peptides and
proteins (26–200 residues) at an extremely fast rate;13 PCY1 is
a naturally occurring promiscuous macrocyclase for smaller
peptides (5–9);14 PoPB macrocyclises the a-amanitin precursor
peptide15 and PatGmac,16 is a highly promiscuous macrocyclase
from the cyanobactins, a family of heterocycle-containing
peptides.17 A principal limitation of these enzymes is that they
operate on peptide substrates; yet a general enzyme catalysed
synthesis of macrocycles is highly desirable.
PatGmac requires a C-terminal recognition sequence AYD
(which is cleaved oﬀ during macrocyclisation) and either thia-
zoline or L-proline immediately preceding the recognition tag.
The ring is thought to be essential as it adopts either a cis-
(proline) or cis-like (thiazoline) conformation allowing the sub-
strate (core) peptide to curve away from the enzyme.16a,b,d,e,17b
Consequently, there are only a few interactions with the core
peptide and very few restrictions on substrate. Those restrictions
include no D-amino acids at either the N-terminus or either
of the last two C-terminal positions of the core peptide.16a,e
PatGmac has a broad substrate scope including non-natural
amino acids,16a peptides with up to three 1,2,3-triazole
rings,16d non-amino acidic scaﬀolds including sugars, benzene
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rings, alkyl and PEG chains16e (Fig. 1). Hybrid peptide non-
peptide molecules with only three amino acids including the
terminal L-Pro/thiazoline have been made.16e Structural biology
has rationalised the requirement for this conformation-inducing
terminal residue. The requirement does limit the scope of the
enzyme and always results in a proline/thiazoline in the final
product.
Here we explored options to remove the requirement for a
thiazoline/L-Pro residue at the C-terminus of the core peptide.
We have used 1,4-anti-1,2,3-triazole-alanine18 and vicinal cysteine
disulphide bonds19 as replacements for L-Pro. The former has
allowed the synthesis of fully non-peptidic macrocycles using
enzymes, whilst the latter allows for the generation of non-
heterocycle containing macrocycles that can vary conformation
in response to redox conditions.
From structural analysis, we hypothesised that one or both
hydrogen bonds between the C-terminus of the core peptide in
the substrate and the enzyme was critical for recognition (Fig. 2).17b
We designed, synthesised and tested range of substrates with an
insertion of a 1,4-disubstituted anti-triazole-alanine at the C-terminus
of the core peptide (position 8) (Table 1). The 1,4-anti-triazole is easily
obtained using Cu(I) catalysis and can be achieved on solid phase
during peptide synthesis.16d,20 We first used propargylamine for the
triazole (Tz1–4) formation, as this glycine mimic was commercially
available. The alanine azido-acid counterpart was synthesised in one
step by a diazo transfer reaction from commercial alanine21 Peptides
1–3 were synthesised with Gly–Tz1–4–Ala dipeptide mimic at the
C-terminus (positions 7 and 8) but all failed to yield the desired
product. Only unreacted starting peptide remained in solution,
indicating the peptide was not a PatGmac substrate. To explore if
the 1,4-anti-triazole precluded a cis-like conformation, the 1,5-
disubstituted syn-triazole (Tz1–5) was employed with Gly–Tz1–5–Ala
dipeptide mimic at positions 7 and 8 of the precursor peptide.
Neither Ru(Cp*Cl(PPh3)2) nor RuCp*(cod)Cl catalysts
22 gave a useful
amount of fully protected dipeptide Gly–Tz1–5–Ala. The thermal
reaction between Fmoc-protected propargylamine and the alanine
azido benzylic ester afforded a 1 :2 ratio of syn- to anti-triazole. The
carboxylic ester of the triazole-containing dipeptides was then
hydrolysed and the regioisomeric mixture was used as a building
block in the peptide synthesis to generate peptides 2/4 and 3/5. The
regioisomeric triazole-containing peptides of both sequences were
separated by HPLC but 1,5-syn-triazole peptides 4 and 5 gave
the same negative result as their corresponding Tz1–4 peptides
Fig. 1 PatG substrates: (A) accepted substitutions within final product are
shown in blue, but so far require proline or thiazoline (orange). (B) Triazole
and double cysteine bypass this requirement. (C) Macrocycles synthesized
with PatGmac so far.16d,e
Fig. 2 Left: Hydrogen bonding between the side chain of Asn717 and the
carbonyls of substrate. We conclude these hydrogen bonds are critical in
substrate recognition and explain the requirement for an L-configured
non-glycine residue at position residues 7 of substrate (Phe is shown from
PDB 4AKT). Right: PatGmac macrocyclisation substrate requirements: a
heterocycle before AYD adopting a cis- or cis-like conformation, a side
chain (R Z Me) preceding the heterocycle. We conclude two substrate
carbonyls (coloured green & pink) hydrogen bonded with Asn717 are
critical.
Table 1 Synthetic peptides 1–26, the resulting PatGmac reaction out-
come, and isolated macrocyclic peptides and their yields
Peptide Substrate sequencea Productb Cyclicc Yieldd (%)
1 NR
2 NR
3 NR
4 NR
5 NR
6 NR
7 C
8 C 8c16d 32
9 NR
10 NR
11a C 11c/d 40
11b NR
12 NR
13a NR
13b NR
14 C 14c 40
15 C
16 C 16c/d 36
17 C 17c 34
18 C
19 C (L) 19c 37
20 L
21 NR
22 L
23 NR
24 C
25 C (L)
26 C (L)
a Underlined is the minimal recognition sequence AYD where the
peptide is cleaved. Tz1–4 = 1,4-anti-triazole, Tz1–5= 1,5-syn-triazole, bA
= b-alanine, b2-homoA = (R)-3-amino-2-methylpropanoic acid, D-amino
acids in lower case, [CC] = disulphide bond. b NR = No reaction, C =
Cyclic, L = Linear; major product shown in table, minor product shown
in brackets. c Isolated macrocycles. d Their yields.
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(cf. peptides 2 and 4, 3 and 5 in Table 1). The structure of PatGmac
H618A in complex with a proline-containing substrate (PDB 4AKT)17b
reveals a binding pocket for the side chain of position 7 (Fig. 2). We
hypothesised that a side chain at position 7 might be necessary to
rigidify the peptide and thus favour the hydrogen bond. In order to
test this hypothesis, peptides 6 and 7 with a proline preceded by a
glycine and alanine (phenylalanine 8 at this position has been
previously shown to be a substrate)16d were tested. Peptide 6 (Gly)
was unchanged by the enzyme but peptide 7 (Ala) was processed to
afford cyclic peptide, at essentially the same rate and efficiency as
PatGmac peptide substrates.We concluded a side chain at position 7
is required to properly orient substrate tomake the second hydrogen
bond. The requirement for both hydrogen bonds also rationalises
why peptides containing b-alanine (9) or (R)-3-amino-2-methyl-
propanoic acid ((R)-b2-homoalanine) (10), which move the amide
out of position due to an extra carbon, were not processed by the
enzyme.
Having established the importance of position 7, we
modified our design strategy. We synthesized peptide 11 with
Phe–Tz1–4–Ala dipeptide mimic at the C-terminus. The phenyl-
alanine amino alkyne derivative was synthesised in five steps
starting from the commercial Boc protected amino acid, as
previously described.16d Epimerisation of phenylalanine amino
alkyne occurred for the phenylalanine derivative during synth-
esis affording a mixture of inseparable enantiomers. The final
diastereomeric peptides however were easily separated by
HPLC affording peptides 11a and 11b. The major diastereomer
11a was macrocyclised by PatGmac, whereas the minor diaster-
eomer 11b did not. Since D-amino acids at positions 7 (the
control peptide 12 with a D-Phe at position 7 failed to give the
corresponding macrocycle) and D amino acids at position 8
have been reported not to be tolerated,16a 11b was assigned as
having one D-amino acid at the triazole, either position 7 or 8
and does not process. The macrocyclisation of peptide 11a
demonstrates for the first time that the L-Pro requirement can
be dispensed with and consistent with knowledge of the system
is assumed to be L-Phe–Tz1–4–L-Ala. Deletion of the methyl
group to afford Phe–Tz1–4–Gly dipeptide mimic (peptides 13a, b)
afforded no product in the presence of PatGmac, as expected. The
dipeptide mimic Ala–Tz1–4–Ala 14 was a substrate as was peptide
15, which has two triazole units. This led us to conclude that
replacing L-Pro with the triazole group did not diminish our ability
to introduce other modifications elsewhere in the core peptide. In
order to explore these limits, peptide 16 having one amino acid at
the N-terminus linked by a PEG chain was tested and macro-
cyclised. Peptides 17 and 18, which have no a amino acids in the
core, but have a free amine on a PEG group, gave macrocyclic
compounds.
We then explored the use of vicinal L-cysteine disulphide
bond as an alternative to proline, a defining motif of three
important cyclic peptide families that are biologically active:
malformins, somatostatins, and conotoxins.23 The disulfide
bond containing substrate peptides (19–26) were synthesised
by standard solid phase peptide synthesis and isolated as free
cysteine-containing peptides and then oxidised overnight in
10% DMSO in TFA. Peptides 19 and 20 were designed as a
positive and negative controls as 19mimics 8, a good substrate,
whilst 20 mimics VPAPIPFP a poor substrate that mainly gives
linear peptide.17b Analysis after two days of incubation showed
that peptide 19 gave mainly macrocyclic peptide whereas
peptide 20 gave only cleaved linear peptide. Peptide 21 with
the D-cysteine motif (akin to malformins)23 did not macro-
cyclise. We took these results as confirming that vicinal
L-cysteine disulphide bond could replace L-Pro and we explored
derivatives of the remaining natural product families with this
motif. Cyclic hexapeptidic analogues of somatostatin-
containing YwKT or FwKT and a vicinal cysteine disulphide
bond were reported to be more potent than the natural
product.23 Peptide 22 was designed to produce such an analo-
gue, but mainly yielded cleaved peptide, most likely because of
the PatGmac preference for longer peptides.16e As a final test we
explored conotoxin cyclic analogues24 23–26. The hexapeptide
23 did not react; however the other hepta- and octa-peptide
substrates all gave the desired cyclic peptides. PatGmac does
afford facile access to analogues of conotoxin. We confirmed
that reduction of the disulfide bond of macrocyle 19c by TCEP
in methanol/water was possible after macrocyclisation to give
peptide 19d (ESI†). This result opens the possibility of redox
control of the macrocycle structure.
Products were identified by MALDI-MS and further verified
by MS–MS fragmentation data (ESI†). Where the reactions were
carried out at scale, macrocycles (Fig. 3) were isolated, purified
by HPLC, and characterised using HRMS and NMR (ESI†). We
observed moderate yields (32–40%) with an incubation of two
weeks at 37 1C and pH = 8.1. Cyclic peptides derived from 11a
and 16 purified as two HPLC separable peaks with identical
chemical composition determined by NMR and HRMS. EXSY
NMR analysis indicates that they are not readily exchangeable
conformers, suggesting these are either diasteriomers or struc-
turally rigid conformers unable to interconvert (atropisomers).
Spontaneous epimerization of macrocycles is known,25 but
seems less likely for alpha position of a triazole. PatGmac does
not process peptide substrates with D-amino acids at either
position 7 or 8, it maybe the triazole leads to PatGmac tolerating
substrate D-configuration. Cyclic peptide 17c purified as a single
peak, but proton NMR identified a minor (o5%) conformer.
Fig. 3 Non-proline containing macrocycles macrocyclised by PatGmac.
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Macrocycle 14c has in addition to the predominant conformer
other minor conformers. Macrocycle 19c gave rise to a complex
spectrum, showing one major compound with at least two other
minor conformers that were not fully identified.
Macrocyclisation is an important and essential transforma-
tion in nature in general, and for the synthesis of biologically
active molecules. Many enzymes in nature are involved in ring
closure reactions, but are usually restricted to their biosynthetic
pathway. Indeed, biocatalysis in general can be very eﬃcient in
conducting certain reactions, however this usually comes at a
very high price in terms of substrate specificity. Hence, the
ability to macrocyclise a range of structurally diﬀerent com-
pounds is a huge advantage allowing for a wider diversity.
Herein we show that PatGmac is able to macrocyclise cyclic
peptides containing non-natural and natural proline mimics at
the C-terminus of the core peptide, a position that was thought
to be restricted to natural heterocycles. We were able to
synthesize macrocyclic compounds with no amino acids or no
heterocycles. This very broad substrate range of PatGmac
expands the scope of its applications, despite its slower rate
and moderate yields. Nonetheless, further improvement of the
catalytic eﬃciency of the enzyme achieved by directed
evolution26 or protein engineering would be valuable. To the
best of our knowledge, PatGmac is the first described peptidic
ligase capable of macrocyclising non-peptidic precursors, mak-
ing it the first enzymatic tool employed for the generation of
diverse macrocyclic libraries.
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